Travere Therapeutics(US:TVTX)2026-02-19 22:32Financial Data and Key Metrics Changes - For Q4 2025, the company reported U.S. net product sales of $126.6 million, with total net product sales for the full year reaching $410.5 million, marking significant year-over-year growth [24][29] - FILSPARI generated approximately $103 million in net product sales for Q4 2025, resulting in $322 million for the full year, representing a 144% year-over-year growth [19][24] - The company achieved a net income of $2.7 million for Q4 2025, compared to a net loss of $60.3 million for the same period in 2024 [29] Business Line Data and Key Metrics Changes - FILSPARI saw record demand with 908 new patient starts in Q4 2025, driven by strong physician adoption and confidence in its role as a foundational therapy in IgA nephropathy [18][19] - Thiola and Thiola EC contributed $23.3 million in U.S. net product sales during Q4 2025, totaling $88.5 million for the full year [25] Market Data and Key Metrics Changes - The company noted that over 96% of the patient population has a pathway to reimbursement for FILSPARI, indicating strong payer support despite new competition [37] - There is increasing adoption of FILSPARI among patients with proteinuria levels below 1.5 grams per gram, which represents approximately two-thirds of the addressable IgA nephropathy population [21] Company Strategy and Development Direction - The company aims to solidify FILSPARI's foundational role in IgA nephropathy, successfully deliver the first approved medicine for FSGS, and advance enrollment in the Phase 3 HARMONY Study [9][30] - The strategy includes expanding the commercial team and preparing for a potential launch in FSGS, which is expected to be a larger opportunity compared to IgA nephropathy [22][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of FILSPARI in IgA nephropathy and the potential for FSGS, emphasizing the urgency to deliver meaningful progress for patients [5][32] - The company anticipates meaningful net product sales growth from FILSPARI and IgA nephropathy, with a focus on thoughtful investments to support long-term growth [30][31] Other Important Information - The company received a major amendment notification for its sNDA for FSGS, with a new FDA PDUFA target action date set for April 13, 2026 [7][8] - Pegtibatinase for classical homocystinuria is also advancing, with resumed site activation for the pivotal Phase 3 HARMONY study [8][16] Q&A Session Summary Question: Can you provide more detail on IgA performance and the prescribing landscape? - Management noted strong demand driven by REMS modifications and KDIGO publication, with the majority of utilization occurring in community settings [35][37] Question: Have there been significant data requests from the FDA regarding FSGS? - Management confirmed ongoing engagement with the FDA and expressed confidence in the data supporting FILSPARI's potential treatment for FSGS [46][68] Question: What is the sales infrastructure for IgAN and how will it expand for FSGS? - The prescriber base for FSGS is similar to IgA nephropathy, with an expanded field team already operational to optimize opportunities [57][60] Question: How do you view FILSPARI's market penetration and growth potential? - Management indicated that FILSPARI has not yet penetrated 10% of the addressable patient population, suggesting significant growth opportunities ahead [77][80]